A phase II study of bortezomib in the treatment of metastatic malignant melanoma-Reference-Cited by-同舟云学术

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

Published:2005 Issue:12 Volume:103 Page:2584-2589
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Markovic Svetomir N.,Geyer Susan M.,Dawkins Fitzroy,Sharfman William,Albertini Mark,Maples William,Fracasso Paula M.,Fitch Tom,LoRusso Patricia,Adjei Alex A.,Erlichman Charles

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer

2. Protease inhibitor-induced apoptosis: accumulation of wt p53, p21WAF1/CIP1, and induction of apoptosis are independent markers of proteasome inhibition

3. Proteasome inhibition in cancer: Development of PS-341

4. Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic Malignancies

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of α-Amidobenzylboronates as Highly Potent Covalent Inhibitors of Plasma Kallikrein;ACS Medicinal Chemistry Letters;2024-03-28

2. SKping cell cycle regulation: role of ubiquitin ligase SKP2 in hematological malignancies;Frontiers in Oncology;2024-03-15

3. Clinical Experience on Proteasome Inhibitors in Cancer;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

4. Effects of NF-κB manipulation on cancer-associated bone disease;Bone Cancer;2022

5. Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line;Medical Oncology;2021-08-07